Jan 24 (Reuters) - Merck's ( MRK ) blockbuster drug
Keytruda and Eisai's ( ESALF ) cancer drug Lenvima, in
combination with chemotherapy, failed to improve overall
survival in patients with a type of esophageal cancer in a
late-stage trial, the companies said on Friday.